Tumour markers;Tumormarker

Acta Medica Austriaca

Volumn 28, Issue 2, 2001, Pages 33-37

  Fiebiger, W ^a   Wiltschke, C ^a  

^a St Anna Kinderspital   (Austria)

Author keywords

AFP; CA 125; CA 15 3; CA 19 9; CEA; CYFRA; NSE; PSA; SCC; Tumour markers; HCG

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; PROSTATE SPECIFIC ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

CANCER; CANCER LOCALIZATION; CANCER SCREENING; DIAGNOSTIC ACCURACY; HUMAN; INFLAMMATORY DISEASE; MALIGNANT TRANSFORMATION; PATIENT MONITORING; PROGNOSIS; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; NEOPLASMS; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0035031057     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1563-2571.2001.01008.x     Document Type: Review

References (13)

1. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
2. Tumormarker bei dialysepflichtiger niereninsuffizenz. Ein verleich der antigene MCA, CA 15-3, CA125, CA 19-9, und CEA
3. Tumor marker measurements in the diagnosis and monitoring of breast cancer
4. Alte und neue tumormarker
5. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21-1 in resectable non-small cell lung cancer
6. Tumormarker
7. Long-term follow up study in brest cancer patients using serum tumor markers CEA and CA 15-3
8. Recognizing abnormal marker results do not reflect disease in patients with germ cell tumors
9. Prostate-specific antigen as a marker of prostate disease
10. Recognizing abnormal marker results do not reflect disease in patients with germ cell tumors
11. NIH consensus conference. Ovarian cancer, screening, treatment, and follow-up
12. Tumormarker
13. Tumor marker at the time of recurrence in patients with germ cell tumors